Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Year : 2001  |  Volume : 22  |  Issue : 1  |  Page : 15

Rituximab-monoclonal antibody


Department of Medical Oncology Gujarat Cancer and Research Institute, Amdavad, Gujarat, India

Correspondence Address:
B Shah
Department of Medical Oncology Gujarat Cancer and Research Institute, Amdavad, Gujarat, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

In 1997, Rituximab became the first unconjugated monoclonal antibody to gain FDA-approved labelling for use in cancer therapy. Rituximab is currently indicated for use in the treatment of adult patients with relapsed or refractory low-grade or follicular CD20-positive B-cell NHL. Rituximab is an alternative to conventional chemotherapy for the treatment of patients with relapsed or refractory low-grade or follicular CD20-positive B-cell NHL. An over-all response rate of 48 percent has been reported in these patients. Adverse reactions tend to be mild and occur most commonly during the first infusion and in patients with a large tumour burden. Study results for patients with bulky disease or receiving a second course of rituximab therapy are encouraging.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed665    
    Printed49    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal